October 1, 2015
NIH totals $85M for BRAIN initiative in 2015
The National Institutes of Health has shared its second wave of grants to support the goals of the Brain Research through…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
September 28, 2015
Anavex: Phase 2a clinical trial of ANAVEX 2-73 completed
Anavex Life Sciences Corp, a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS)…
September 26, 2015
Janssen’s daratumumab accepted for treatment of European patients with heavily pre-treated multiple myeloma
Janssen-Cilag International NV has announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European…
September 25, 2015
Recall of Murfy Farm’s alfalfa hay
Murphy Farm Hay and Feed Company of Louisburg North Carolina have initiated a voluntary limited recall of alfalfa hay due to…
September 25, 2015
Tresiba and Ryzodeg get FDA’s approval
The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to…
September 25, 2015
Johnson & Johnson completes divestiture of Splenda Brand to Heartland Food Products Group.
Johnson & Johnson Consumer Inc. has completed the divestiture of Splenda Brand to Heartland Food Products Group. Johnson & Johnson announced…
September 25, 2015
Novartis: New NIBR director named. Entresto closer to be available EU
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
September 25, 2015
‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries
Novartis has announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and…
September 23, 2015
NIh: Clomiphene shows better results than letrozole for unexplained infertility
Treatment with clomiphene, a standard therapy for couples with unexplained infertility, results in more live births than treatment with a…
September 23, 2015
Phase 3 study of ABP 215 meets its endpoints
Amgen and Allergan plc. announced on Wednesday that a Phase 3 study of biosimilar candidate ABP 215 met its primary…